ReviewMolecular neurobiology2026
Unravelling Epigenetic Modulation via MicroRNA Delivery: A Therapeutic Frontier for Alzheimer's.
Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is a common form of dementia that primarily affects the elderly population. Several signalling pathways, including Wnt/β-catenin and PI3K/Akt, are significantly affected, disrupting normal physiological processes such as neurogenesis, neuronal survival, neuroinflammation, and BBB disruption, all of which contribute to the progression of AD-like conditions. The current study seeks to investigate and evaluate the involvement of the PI3K-Akt and Wnt/β-catenin pathways in AD, as well as epigenetic regulators that may alter these pathways and be employed as a treatment to improve AD-like conditions. A class of epigenetic regulators known as miRNAs, or short non-coding RNAs, greatly affects gene expression by preventing translation or encouraging target gene destruction. This review will focus on how miRNAs affect Aβ peptide accumulation, hyperphosphorylated tau protein aggregation, and neuroinflammation. In addition, miRNA delivery through exosomes, a lipid nanoparticle, has also been explored in later sections. Our knowledge will assist in creating new miRNA-based therapeutics involving mimics/inhibitors and advance our understanding of how miRNAs control gene expression.
Indexed as
Identifiers
41840318What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.